



Cadila Healthcare Limited

Registered Office : Zydus Tower , Satellite Cross Roads, Ahmedabad - 380015.

Tel. No. (+91-79) 2686 8100 Fax No. : (+91-79) 2686 2365/66 Website : www.zyduscadila.com

Unaudited [Provisional] Financial Results for the Quarter ended December 31, 2005.

CONSOLIDATED					Sr.No.	Particulars	COMPANY					
Rupees in Millions							Rupees in Millions					
Quarter ended on December 31,	Nine Months period ended on December 31,		Previous Accounting Year ended on March 31, 2005				Quarter ended on December 31,	Nine Months period ended on December 31,		Previous Accounting Year ended on March 31, 2005		
2005	2004 [*]	2005	2004 [*]	Audited	2005	2004	2005	2004	Audited			
3869	3324	11577	10311	13051	1	A	Gross Sales	3328	2910	10178	9184	11253
174	130	488	485	621		B	Less : Excise Duty	172	130	486	483	619
3695	3194	11089	9826	12430		C	Net Sales	3156	2780	9692	8701	10634
127	73	341	216	378	2		Other Income	179	150	621	501	785
3822	3267	11430	10042	12808	3		Total Income	3335	2930	10313	9202	11419
					4		Expenditure :					
-101	-257	-167	-214	-361		A	Increase [-] / Decrease in Stock in Trade	-103	-221	-186	-119	-293
1500	1575	4458	4165	5201		B	Consumption of Materials	1367	1389	4016	3673	4604
495	404	1363	1154	1606		C	Staff Cost	420	350	1156	1000	1405
1151	977	3510	2961	3905		D	Other Expenditure	917	804	3010	2633	3308
3045	2699	9164	8066	10351		E	Total Expenditure	2601	2322	7996	7187	9024
777	568	2264	1976	2457	5		Profit before Interest , Depreciation & Tax	734	608	2317	2015	2395
49	56	143	170	210	6	A	Interest & Financial Charges	37	44	107	139	172
54	-73	72	25	35		B	Exchange Rate Fluctuations on Foreign Currency Loans	54	-73	72	20	30
103	-17	215	195	245		C	Total Financial cost	91	-29	179	159	202
674	585	2051	1781	2212	7		Profit before Depreciation & Tax	643	637	2138	1856	2193
214	201	585	529	716	8		Depreciation & Amortisation	153	151	453	435	565
460	384	1466	1252	1496	9		Profit before Tax & Exceptional Items	490	486	1685	1421	1628
14	32	89	94	125	10		Less : Exceptional Items - VRS Expenses	13	31	86	93	124
446	352	1377	1158	1371	11		Profit before tax	477	455	1599	1328	1504
22	21	103	74	86	12		Provision for Taxation					
24	40	61	100	106			- Current Tax	22	20	103	73	84
3	0	10	0	0			- Deferred Tax	23	40	60	100	106
49	61	174	174	192			- Fringe Benefit Tax	3	0	10	0	0
397	291	1203	984	1179			- Total provision for taxation	48	60	173	173	190
-1	0	15	0	36	13		Profit after tax	429	395	1426	1155	1314
396	291	1218	984	1215	14		Adjustments on consolidation	0	0	0	0	0
314	314	314	314	314	15		Net Profit	429	395	1426	1155	1314
6.31	4.63	19.39	15.67	19.34	16		Paid up Equity Share Capital [Face Value Rs. 5 /-]	314	314	314	314	314
				5620	17		Reserves excluding Revaluation Reserve					5830
				19.34	18		E P S [Rs.] [For the period - not Annualised]	6.83	6.29	22.70	18.39	20.93
					19		Aggregate of Non-promoter Shareholding :					
							- Number of Equity Shares	17575229	17741969	17575229	17741969	17575229
							- Percentage of Shareholding	27.98%	28.25%	27.98%	28.25%	27.98%

Notes :

- [1] Above unaudited results were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on January 28, 2006.
- [2] The statutory auditors of the Company have carried out a limited review of the financial results of the Company for & upto the third quarter ended December 31, 2005.
- [3] [*] To give meaningful comparison, the consolidated figures for and upto the previous quarter ended on December 31, 2004, the reporting period of all the foreign subsidiaries and a joint venture Company has been restated to align with that of the reporting period of the Holding company.
- [4] USFDA has approved two more ANDAs filed by the Company to market Generic products in US market.
- [5] The Company has filed 2nd INDA with USFDA.
- [6] France Regulatory has approved one product of the Company to market in France market.
- [7] The Company has entered into a 50 : 50 joint venture with Bharat Serums and Vaccines Limited to develop, manufacture & market NDDS anti cancer product.
- [8] The investor complaints - pending at the beginning of the quarter - 1, received during the quarter - 52, disposed off during the quarter- 53, pending at the end of the quarter - Nil.
- [9] The Company has one segment of activity viz. " Pharmaceuticals ".

By Order of the Board,
For Cadila Healthcare Limited,

Pankaj R.Patel
Chairman & Managing Director

Goa, January 28, 2006.

